Alisertib (MLN8237), a selective Aurora-A kinase inhibitor, induces apoptosis in human tongue squamous cell carcinoma cell both in vitro and in vivo

[1]  Gong Yang,et al.  Corrigendum to “Aurora-A controls cancer cell radio- and chemoresistance via ATM/Chk2-mediated DNA repair networks” [Biochim. Biophys. Acta 1843 (2014) 934–944] , 2014 .

[2]  Gong Yang,et al.  Aurora-A controls cancer cell radio- and chemoresistance via ATM/Chk2-mediated DNA repair networks. , 2014, Biochimica et biophysica acta.

[3]  I. Lossos,et al.  Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Reeder,et al.  Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia , 2013, Investigational New Drugs.

[5]  R. Versteeg,et al.  Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma , 2013, British Journal of Cancer.

[6]  Henk M. W. Verheul,et al.  Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis , 2013, British Journal of Cancer.

[7]  Feimeng Zheng,et al.  Inhibition of mTOR Pathway Sensitizes Acute Myeloid Leukemia Cells to Aurora Inhibitors by Suppression of Glycolytic Metabolism , 2013, Molecular Cancer Research.

[8]  T. Miller,et al.  Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. , 2013, Leukemia research.

[9]  B. Liu,et al.  Inhibition of p21-activated kinase 4 expression suppresses the proliferation of Hep-2 laryngeal carcinoma cells via activation of the ATM/Chk1/2/p53 pathway. , 2013, International journal of oncology.

[10]  F. Giles,et al.  Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO‐dependent mechanism , 2012, International journal of cancer.

[11]  Jie Xu,et al.  Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells , 2012, Autophagy.

[12]  K. Venkatakrishnan,et al.  Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations , 2012, Clinical Cancer Research.

[13]  Rachel E. Gershman,et al.  Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays , 2011, Clinical Cancer Research.

[14]  Arijit Chakravarty,et al.  Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. , 2011, Cancer research.

[15]  Jian Wang,et al.  Inhibition of proliferation, viability, migration and invasion of gastric cancer cells by Aurora-A deletion. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[16]  Jeffrey Ecsedy,et al.  A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. , 2009, Blood.

[17]  J. Petrini,et al.  Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. , 2009, DNA repair.

[18]  I. Vernos,et al.  Dissecting the role of Aurora A during spindle assembly , 2008, The EMBO journal.

[19]  N. Keen,et al.  Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. , 2007, Journal of medicinal chemistry.

[20]  H. Saya,et al.  Aurora-A — A guardian of poles , 2005, Nature Reviews Cancer.

[21]  Stephen S. Taylor,et al.  Aurora-kinase inhibitors as anticancer agents , 2004, Nature Reviews Cancer.

[22]  Kaori Sasai,et al.  Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53 , 2004, Nature Genetics.

[23]  W. Earnshaw,et al.  The cellular geography of Aurora kinases , 2003, Nature Reviews Molecular Cell Biology.

[24]  P. Meraldi,et al.  Aurora‐A overexpression reveals tetraploidization as a major route to centrosome amplification in p53−/− cells , 2002, The EMBO journal.

[25]  Erich A. Nigg,et al.  Cell division: Mitotic kinases as regulators of cell division and its checkpoints , 2001, Nature Reviews Molecular Cell Biology.

[26]  D. Broccoli,et al.  p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. , 1999, Science.